progression free survival
All patients received first-line combined chemotherapy with Gemcitabine Oxaliplatin then evaluated by using RECIST standards for solid tumor response, progression free survival (PFS) and overall survival (OS).
All patients received first-line combined chemotherapy with Gemcitabine Oxaliplatin then evaluated by using RECIST standards for solid tumor response, progression free survival ( PFS ) and overall survival ( OS ) .